The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder
Open accessAbstract
The rare skin disorder pachyonychia congenita (PC) is an autosomal dominant syndrome that includes a disabling plantar keratoderma for which no satisfactory treatment is currently available. We have completed a phase Ib clinical trial for treatment of PC utilizing the first short-interfering RNA (siRNA)-based therapeutic for skin. This siRNA, called TD101, specifically and potently targets the keratin 6a (K6a) N171K mutant mRNA without affecting wild-type K6a mRNA. The safety and efficacy of TD101 was tested in a single-patient 17-week, prospective, double-blind, split-body, vehicle-controlled, dose-escalation trial. Randomly assigned solutions of TD101 or vehicle control were injected in symmetric plantar calluses on opposite feet. No adverse events occurred during the trial or in the 3-month washout period. Subjective patient assessment and physician clinical efficacy measures revealed regression of callus on the siRNA-treated, but not on the vehicle-treated foot. This trial represents the first time that siRNA has been used in a clinical setting to target a mutant gene or a genetic disorder, and the first use of siRNA in human skin. The callus regression seen on the patient's siRNA-treated foot appears sufficiently promising to warrant additional studies of siRNA in this and other dominant-negative skin diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
The promises and pitfalls of RNA-interference-based therapeutics
Castanotto, D., & Rossi, J. J. (2009) · Nature · doi:10.1038/nature07758 · Cited by 1,221
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 929
DEVINCENZO, J., CEHELSKY, J., ALVAREZ, R., ELBASHIR, S., HARBORTH, J., TOUDJARSKA, I., NECHEV, L., MURUGAIAH, V, VLIET, A., & VAISHNAW, A. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2007.11.009 · Cited by 247
Clinical and Pathological Features of Pachyonychia Congenita
Leachman, S. A., Kaspar, R. L., Fleckman, P., Florell, S. R., Smith, F. J. D., McLean, W. H. I., Lunny, D. P., Milstone, L. M., van Steensel, M. A. M., Munro, C. S., et al. (2005) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1111/j.1087-0024.2005.10202.x · Cited by 209
Self-citationStability Study of Unmodified siRNA and Relevance to Clinical Use
Hickerson, R. P., Vlassov, A. V., Wang, Q., Leake, D., Ilves, H., González-González, E., Contag, C. H., Johnston, B. H., & Kaspar, R. L. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0149 · Cited by 136
Self-citationTherapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita
Leachman, S. A., Hickerson, R. P., Hull, P. R., Smith, F. J. D., Milstone, L. M., Lane, E. B., Bale, S. J., Roop, D. R., McLean, W. H. I., & Kaspar, R. L. (2008) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2008.04.003 · Cited by 119
Self-citationSingle-Nucleotide-Specific siRNA Targeting in a Dominant-Negative Skin Model
Hickerson, R. P., Smith, F. J. D., Reeves, R. E., Contag, C. H., Leake, D., Leachman, S. A., Milstone, L. M., McLean, W. H. I., & Kaspar, R. L. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701060 · Cited by 115
Self-citationRNAi therapeutics: an update on delivery.
Nguyen, T. A., Menocal, E. M., Harborth, J., & Fruehauf, J. H. (2008) · PubMed · Cited by 111
The Business of RNAi Therapeutics
Haussecker, D. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.007 · Cited by 87
Cited by
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
LncRNA: A link between RNA and cancer
Yang, G., Lu, X., & Yuan, L. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.08.012 · Cited by 991
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Metadata
- Authors
- Leachman, S. A., Hickerson, R. P., Schwartz, M. E., Bullough, E. E., Hutcherson, S. L., Boucher, K. M., Hansen, C. D., Eliason, M. J., Srivatsa, G. S., Kornbrust, D. J., Smith, F. J., McLean, W. I., Milstone, L. M., & Kaspar, R. L.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 18
- Issue
- 2
- Pages
- 442-446
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2057080391
- Cited by
- 265
- References
- 10
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder. https://app.cochat.ai/papers/10.1038/mt.2009.273
- The paper
- Leachman, S. A., Hickerson, R. P., Schwartz, M. E., Bullough, E. E., Hutcherson, S. L., Boucher, K. M., Hansen, C. D., Eliason, M. J., Srivatsa, G. S., Kornbrust, D. J., Smith, F. J., McLean, W. I., Milstone, L. M., & Kaspar, R. L. (2010). First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder. Molecular Therapy. https://doi.org/10.1038/mt.2009.273
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.